V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011923 | 330005792 | 0 | 92.7 | Palliative (P) | 2014-11-21 | 2015-01-08 | FCiSt | null | N | 330023816 | UKALL XII |
| 330011924 | 330005794 | 1.8 | null | Curative (C) | 2013-12-14 | 2014-01-07 | IVA | N | N | 330023819 | FLUOROURACIL + MITOMYCIN + RT |
| 330011925 | 330005802 | 1.74 | 74.6 | Palliative (P) | 2016-06-02 | 2016-06-02 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | null | 330023868 | EDP + MITOTANE |
| 330011926 | 330005805 | 1.6 | 72.7 | Curative (C) | 2013-05-03 | 2013-06-08 | Mitotane 5.5 - 10g | 2 | N | 330023874 | UKALL XII |
| 330011927 | 330005808 | 1.4 | 124.5 | Curative (C) | null | 2017-09-07 | Erlotinib | N | null | 330023886 | PONATINIB |
| 330011928 | 330005814 | 1.74 | null | Palliative (P) | 2015-05-05 | 2015-05-05 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | N | 330023933 | OFATUMUMAB |
| 330011929 | 330005819 | 1.49 | 56 | Curative (C) | 2016-09-14 | 2016-10-03 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330023951 | MAP + MIFAMURTIDE |
| 330011930 | 330009168 | null | null | Palliative (P) | 2016-05-15 | 2016-06-02 | CVP R | N | null | 330023962 | MITOTANE |
| 330011931 | 330005825 | 1.71 | null | Palliative (P) | 2015-11-02 | 2015-11-16 | MITOTANE | null | N | 330024003 | CASPS TRIAL |
| 330011932 | 330005831 | 0 | 56 | Adjuvant (A) | null | 2014-02-10 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330024059 | DOXORUBICIN + IFOSFAMIDE |
| 330011933 | 330005832 | 1.56 | null | Neo-adjuvant (N) | 2018-04-16 | 2018-06-25 | Mitotane 5.5 - 10g | N | N | 330024076 | IBRUTINIB |
| 330011934 | 330005835 | 1.76 | 63.4 | Disease modification (D) | null | 2014-12-20 | CARBOPLATIN + CETUXIMAB + FU | 2 | N | 330024112 | CETUXIMAB + CISPLATIN + FU |
| 330011935 | 330005838 | 1.66 | 8 | Curative (C) | 2014-02-25 | 2014-07-16 | Bortezomib + Cyclophos + Dex | N | N | 330024125 | CYTARABINE |
| 330011936 | 330009180 | 1.84 | 12.6 | Curative (C) | 2018-03-01 | 2018-03-02 | DACTINOMYCIN + CYCLO + VINCRISTINE | 2 | N | 330024126 | CLADRIBINE |
| 330011937 | 330005844 | 0.83 | 50.4 | Adjuvant (A) | 2014-09-21 | 2017-04-22 | FLAG | N | null | 330024179 | UKALL XII |
| 330011938 | 330005846 | 0 | 55 | Neo-adjuvant (N) | 2016-06-03 | 2018-07-06 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 330024185 | CYTARABINE |
| 330011939 | 330005848 | 1.52 | null | Curative (C) | 2016-05-02 | 2016-05-03 | CYCLOPHOSPHAMIDE | 02 | N | 330024190 | AML18 TRIAL |
| 330011940 | 330012561 | 0.9 | 70 | Palliative (P) | 2017-10-13 | 2018-05-15 | EMA/CO | 2 | N | 330024194 | DOXORUBICIN + OLARATUMAB |
| 330011941 | 330012561 | 1.68 | 122 | Curative (C) | 2014-12-19 | 2014-12-29 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | null | 330024194 | TOPOTECAN |
| 330011942 | 330005850 | null | 148.9 | Palliative (P) | 2018-10-31 | 2018-10-31 | CLADRIBINE | 02 | null | 330024210 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330011943 | 330005852 | 1.5 | 77.2 | null | 2015-12-08 | 2015-12-19 | Cyclophosphamide High Dose | Y | N | 330024239 | IPILIMUMAB |
| 330011944 | 330005854 | 1.62 | 46.7 | Palliative (P) | 2017-10-20 | 2017-10-20 | Cytarabine Low Dose | Y | N | 330024241 | CLOFARABINE + CYTARABINE |
| 330011945 | 330005855 | 1.71 | 66 | Curative (C) | 2017-05-06 | 2017-05-12 | AXI-STS TRIAL | 2 | N | 330024241 | LEAM |
| 330011946 | 330005858 | 1.6 | 0 | Not known (9) | 2014-07-10 | 2014-07-11 | CAP | 01 | N | 330024264 | OXALIPLATIN + MDG |
| 330011947 | 330005860 | 1.69 | 76 | Curative (C) | 2018-05-14 | 2018-05-26 | VINCRISTINE | 02 | N | 330024272 | DACARBAZINE + GEMCITABINE |
| 330011948 | 330005864 | null | 77 | Palliative (P) | 2019-03-13 | 2019-03-13 | Clofarabine + Cytarabine + Idarubicin | N | N | 330024281 | IVA |
| 330011949 | 330005871 | 1.64 | 72 | Palliative (P) | 2013-10-02 | 2013-12-14 | Cytarabine Low Dose | N | N | 330024316 | CAPECITABINE + OXALIPLATIN |
| 330011950 | 330009202 | 1.81 | null | Disease modification (D) | 2016-06-26 | 2016-07-10 | AML17 TRIAL | N | N | 330024378 | BOP |
| 330011951 | 330005882 | 1.91 | 52.1 | Disease modification (D) | 2016-03-13 | 2016-10-02 | Topotecan (intravenous) | 02 | N | 330024385 | IFOSFAMIDE |
| 330011952 | 330005886 | null | null | Curative (C) | 2016-06-29 | 2016-07-13 | Doxorubicin + Ifosfamide | N | N | 330024390 | NILOTINIB |
| 330011953 | 330005890 | null | 77.9 | Palliative (P) | 2015-02-23 | 2015-07-14 | UKALL14- Intens/CNS Proph | N | null | 330024412 | GEMCITABINE |
| 330011954 | 330005894 | 0 | 57.8 | Palliative (P) | 2014-12-06 | 2015-03-12 | CISPLATIN + ETOPOSIDE + PACLITAXEL | N | N | 330024452 | CVD |
| 330011955 | 330011995 | 0 | 65.8 | Palliative (P) | 2017-09-13 | 2017-09-13 | Cytarabine Low Dose | 02 | N | 330024481 | MITOTANE |
| 330011957 | 330005902 | 1.67 | 90.85 | Curative (C) | 2016-02-11 | 2016-02-15 | Vincristine (weekly) | N | N | 330024492 | ALL INTERIM GUIDELINES |
| 330011958 | 330005903 | 1.75 | 29.1 | Palliative (P) | 2017-07-30 | 2017-10-28 | AML17 TRIAL | N | null | 330024495 | LENALIDOMIDE |
| 330011959 | 330005907 | 1.74 | 68.7 | Palliative (P) | 2015-06-17 | 2015-06-17 | Ifosfamide | N | N | 330024539 | MITOTANE |
| 330011960 | 330011008 | 1.73 | 22.2 | Curative (C) | 2014-05-28 | 2014-05-28 | Hydroxycarbamide | null | N | 330024541 | VIDE |
| 330011961 | 330005915 | 1.62 | 52.65 | Curative (C) | 2015-09-27 | 2015-09-27 | Cyclophosphamide oral | N | N | 330024564 | UKALL2014 |
| 330011963 | 330005920 | 1.85 | 80.5 | Adjuvant (A) | null | 2014-02-07 | BEP 3 day | N | N | 330024607 | AML17 TRIAL |
| 330011964 | 330005921 | 1.83 | 101 | Curative (C) | 2013-11-05 | 2014-12-01 | BEP 5 Day | Y | N | 330024608 | AML18 TRIAL |
| 330011965 | 330005923 | 1.64 | null | Curative (C) | 2017-02-25 | 2017-02-25 | VIDE | 02 | N | 330024625 | PONATINIB |
| 330011966 | 330005931 | 0 | 91 | Disease modification (D) | 2016-01-31 | 2016-01-31 | ALL UKALL60+ TRIAL | N | N | 330024744 | IPILIMUMAB |
| 330011967 | 330012890 | 1.81 | 82 | Palliative (P) | 2017-07-16 | 2017-07-21 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 330024755 | CLADRIBINE |
| 330011968 | 330005933 | 1.64 | null | Palliative (P) | 2014-10-02 | 2014-10-18 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | N | 330024769 | FLUOROURACIL |
| 330011969 | 330005937 | 0 | 44.2 | null | 2015-09-13 | 2016-07-04 | EMA | 1 | N | 330024785 | EMA |
| 330011970 | 330005938 | null | 120 | Palliative (P) | 2016-02-25 | 2016-02-25 | Docetaxel + Nintedanib | 2 | N | 330024788 | TRIPLE INTRATHECAL |
| 330011971 | 330005941 | null | 55 | Palliative (P) | 2018-05-07 | 2018-05-07 | CISPLATIN + ETOPOSIDE + PACLITAXEL | N | N | 330024829 | EMA/CO |
| 330011972 | 330005944 | 0 | 77 | Palliative (P) | 2015-11-14 | 2015-12-23 | Cyclophosphamide High Dose | N | N | 330024832 | INTERFERON |
| 330011973 | 330005945 | 1.83 | 62.5 | Palliative (P) | 2014-01-03 | 2014-02-12 | STS Rhabdo VIT0910 Vinc Irinotecan | N | null | 330024851 | TOPOTECAN |
| 330011974 | 330005950 | 0 | 36.4 | Disease modification (D) | 2015-03-27 | 2015-05-29 | Fludarabine + Melphalan RIC Allo | N | N | 330024868 | ERLOTINIB |